...3,800,000 shares short now. They continue to press their case. AMPE needs a deal for Zertane that will include a decent upfront cash payment + future royalties. That would take care of their immediate needs for cash over the next 12 months and put any talk of a dilutive secondary to bed. That would also take some steam out of the short's case.
The real inflection point for AMPE is when we get preliminary results on the Optina & Ampion trials, both of which will be this year.
AMPE has enough cash in the bank to complete the three studies currently underway. If the Ampion study is positive we will have a marketing agreement in 12 weeks. AMPE does not need anything now except for good study results. As you said the study results are the bottom line. Interesting some of the same shorts are battering NAVB. They have continued AFTER their big testing drug was approved by the FDA and a marketing agreement signed. So you never know what is in the mind of a short.
I'm kinda glad to hear about the increase in short interest. I view it as some sort of pent up demand on the buy side in the event of a bump in share price.
AMPE has closed above $5 for four days now. It hasn't done that since December of 2011 when it was in the $7 range (before the 'short attack'). I have a hunch (purely a guess with little basis) that AMPE will not see the $6's. I think news on Zertane or something similar will result in a gap up to the $7+ range. In such an event, the pent-up short covering demand will kick in big time.
Perhaps just wishful thinking, but barring failure of drugs that have already proven themselves, or a huge management blunder, a $400M market cap should be a no brainer. 3.8M shorts will just add more fuel to the fire once its ignited.